Innate PharmaIPHYF 29 PS Ratio is 45.83 as of Jul. 02, 2026, which is 537% above its 10-year median of 7.20. GuruFocus rates IPHYF with a GF Score™ of 29/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 933 Biotechnology companies, Innate Pharma ranks worse than 78.46% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Innate Pharma's share price is $1.65.
Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04. Hence, Innate Pharma's PS Ratio for today is 45.83.
Warning Sign:
Innate Pharma SA stock PS Ratio (=51.42) is close to 10-year high of 56.13.
The historical rank and industry rank for Innate Pharma's PS Ratio or its related term are showing as below:
IPHYF'
s PS Ratio Range Over the Past 10 Years
Min: 2.21 Med: 7.2 Max: 56.13
Current: 51.42
During the past 13 years, Innate Pharma's highest PS Ratio was 56.13. The lowest was 2.21. And the median was 7.20.
IPHYF's PS Ratio is ranked worse than 78.46% of 933
companies
in the Biotechnology industry
Industry Median: 9.46
vs IPHYF: 51.42
Innate Pharma SA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Innate Pharma was -80.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -63.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -35.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -18.70% per year.
During the past 13 years, Innate Pharma's highest 3-Year average Revenue per Share Growth Rate was 221.80% per year. The lowest was -63.20% per year. And the median was -1.35% per year.
Back to Basics: PS Ratio
Innate Pharma (OTCPK:IPHYF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Innate Pharma PS Ratio Related Terms
Innate Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Innate Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innate Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Innate Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Innate Pharma's Share Price of today is $1.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Innate Pharma (IPHYF) has a PS Ratio of 45.83 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Innate Pharma and its competitors. This is 537% above median its historical median of 7.20. Over the past decade, Innate Pharma's PS Ratio has ranged from 2.21 to 56.13. According to the industry distribution chart, Innate Pharma ranks #732 out of 933 companies in the Biotechnology industry, placing it in the top 78.5%.
Is Innate Pharma's PS Ratio too high?
Innate Pharma's current PS Ratio of 45.83 is 537% above median its 10-year median of 7.20. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 56.13. The Biotechnology industry median PS Ratio is 9.46. Innate Pharma's value of 45.83 is 384.5% above this industry median. Based on the distribution chart, Innate Pharma ranks #732 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #732 out of 933 companies for PS Ratio. This places Innate Pharma in the lower half of its industry. The industry median PS Ratio is 9.46. Innate Pharma's value of 45.83 is 384.5% above this benchmark. Historically, Innate Pharma's own PS Ratio has ranged from 2.21 to 56.13 over the past decade. While the company's 10-year median is 7.20 vs. the industry median of 9.46, Innate Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current PS Ratio of 45.83 is 384.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current PS Ratio is 45.83, which is 537% above median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $1.65 — trading 1078.6% above its estimated fair value. The current PS Ratio is 45.83, which is 537% above median its 10-year median of 7.20 and 384.5% above the Biotechnology industry median of 9.46. Innate Pharma's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Innate Pharma (IPHYF), the current PS Ratio is 45.83 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHYF) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.65 is trading 1078.6% above its estimated GF Value™ of $0.14.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHYF:
PS Ratio: 45.83 (537% above median its 10-year median of 7.20)
GF Value™: $0.14 vs. price of $1.65 (1078.6% above fair value)
Industry Position: 384.5% above the Biotechnology median (#732 of 933)
No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
29GF Score
Get the complete analysis for IPHYF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHYF has been successfully added to your 
